International legal practice Osborne Clarke has advised MedAnnex, on its £11.5 million equity investment led by Morningside Ventures, a major investor in the global life sciences sector.
MedAnnex is an award-winning Scottish biotechnology company developing innovative approaches to treating autoimmune diseases and other medical conditions.
The funds will be used in conjunction with recent grant awards from Innovate UK and Scottish Enterprise to accelerate MedAnnex’s research and development activities. In collaboration with experts at a number of academic institutions including UCL, Glasgow University and Anglia Ruskin University, MedAnnex is developing therapeutic antibodies with the potential to treat a range of diseases.
Osborne Clarke’s life science and healthcare sector team has a strong track record of providing highly sophisticated advice to biotech clients on cutting-edge issues, across multiple service lines. They work with the biggest pharma and medical devices companies in the market.